To include your compound in the COVID-19 Resource Center, submit it here.

Apricitabine: Phase III ongoing

An independent DSMB recommended continuation of Avexa's international Phase III trial evaluating apricitabine at the 800 mg dose based

Read the full 199 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE